Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: Eicosapentaenoic acid preserves diaphragm force generation following endotoxin administration. | Supinski et al. Critical Care 2010 14 R35 http content 14 2 R35 c CRITICAL CARE RESEARCH Open Access Eicosapentaenoic acid preserves diaphragm force generation following endotoxin administration Gerald S Supinski Jonas Vanags Leigh Ann Callahan Abstract Introduction Infections produce severe respiratory muscle weakness which contributes to the development of respiratory failure. An effective safe therapy to prevent respiratory muscle dysfunction in infected patients has not been defined. This study examined the effect of eicosapentaenoic acid EPA an immunomodulator that can be safely administered to patients on diaphragm force generation following endotoxin administration. Methods Rats were administered the following n 5 group a saline b endotoxin 12 mg kg IP c endotoxin EPA g kg d and d EPA alone. Diaphragms were removed and measurements made of the diaphragm forcefrequency curve calpain activation caspase activation and protein carbonyl levels. Results Endotoxin elicited large reductions in diaphragm specific force generation P and increased diaphragm caspase activation P calpain activation P and protein carbonyl levels P . EPA administration attenuated endotoxin-induced reductions in diaphragm specific force with maximum specific force levels of 27 1 14 1 23 1 and 24 1 N cm2 respectively for control endotoxin endotoxin EPA and EPA treated groups P . EPA did not prevent endotoxin induced caspase activation or protein carbonyl formation but significantly reduced calpain activation P . Conclusions These data indicate that endotoxin-induced reductions in diaphragm specific force generation can be partially prevented by administration of EPA a nontoxic biopharmaceutical that can be safely given to patients. We speculate that it may be possible to reduce infection-induced skeletal muscle weakness in critically ill patients by administration of EPA. Introduction Infections produce severe respiratory muscle weakness which
